Behcet’s disease and severe inflammatory reaction to 23-valent pneumococcal polysaccharide vaccine: a case report and review of literature

Abstract

Current European League Against Rheumatism guidelines strongly recommend considering the use of polysaccharide pneumococcal vaccine in all patients with autoimmune inflammatory rheumatic diseases. However, a previously published case series reports of reactions to 23-valent pneumococcal polysaccharide vaccine in patients with Behcet’s disease. The purpose of this report is to present a similar case of a systemic adverse reaction in a patient with Behcet’s disease to 23-valent pneumococcal polysaccharide vaccine.

Keywords

Behcet’s disease pneumococcal vaccine vasculitis inflammatory reaction

Get full access to this article

View all access options for this article.

References

Davatchi

Shahram

Chams-Davatchi

et al.

Behcet’s disease in Iran: analysis of 6500 cases. Int J Rheum Dis 2010; 13: 367–373.

Van Assen

Agmon-Levin

Elkayam

et al.

EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011; 70: 414–422.

Direskeneli

. Behçet's disease: infectious aetiology, new autoantigens, and HLA-B51. Ann Rheum Dis 2001; 60: 996–1002.

De Menthon

LaValley

Maldini

et al.

HLA–B51/B5 and the risk of Behçet's disease: a systematic review and meta-analysis of case–control genetic association studies. Arthritis Rheum 2009; 61: 1287–1296.

Little

Nightingale

Verburgh

et al.

Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis 2010; 69: 1036–1043.

Hügle

Bircher

Walker

. Streptococcal hypersensitivity reloaded: severe inflammatory syndrome in Behçet's disease following 23-valent polysaccharide Streptococcus pneumoniae vaccine. Rheumatology 2012; 51: 761–762.